The purpose of this study was to review a single-center comparative experience with these fistulas.

Methods: A retrospective chart review was performed on 59 patients who received basilic and brachial vein transpositions between January 2000 and December 2006. Patient demographics, comorbidities, mortality, and morbidity were evaluated. Patency rates were calculated using Kaplan-Meier life-table analysis.

Results: Of 59 vein

transpositions, there were 42 basilic (71%) and 17 brachial (29%). The 30-day mortality was 0%. Maturation rates were 74% for basilic vein transpositions and 47% for brachial (P = .049). The mean time to maturation was 11.9 +/- 8.8 weeks. Primary patency rates at 12 months were 50% for basilic vein transpositions vs 40% for brachial (P = .115). The mean vein size was 4.9 +/- 0.9 mm. Elafibranor datasheet The mean basilic vein transposition diameter

of 4.9 +/- 1.0 mm and brachial vein transposition diameter of 5.0 +/- 0.8 mm were not significant (P = .39).

Conclusions: Despite a higher rate of initial maturation in basilic vein transpositions, brachial and basilic vein transpositions had comparable patency rates at 12 months. These preliminary results require further follow-up and a larger cohort of patients for confirmation. Broader use of the brachial vein transposition for dialysis appears Selleckchem U0126 justified and can increase the overall percentage of autogenous fistula placement.”
“Doxorubicin (DOX) is an anthracycline anticancer drug considered to be a first line choice in the treatment of breast cancer, childhood solid tumours, soft tissue sarcomas and aggressive lymphomas. Notwithstanding the fact that DOX does not cross the blood-brain barrier, several modified delivery systems have been recently developed to circumvent this obstacle

and use DOX as an effective agent against brain tumours. However, the putative effect of DOX at the CNS remains elusive. Thus, the aim of this work was to investigate and characterise the mode of cell death Sitaxentan induced by the anticancer agent DOX in cortical neurons. The obtained results indicated that DOX is neurotoxic to serum-free cultures of cortical neurons in a biphasic concentration manner: for concentrations up to 0.5 mu M, cell death follows an apoptotic pattern, while for higher concentrations apoptosis is inhibited and necrosis becomes dominant. Apoptosis induced by DOX in our model can occur via different pathways. It is expected that the obtained information from this work can provide new clues about the mechanisms of DOX neurotoxicity that may be of great value for preventing its effects in non-target cells. (C) 2007 Elsevier Inc. All rights reserved.